Uruguay enacted Law 19.172 in December 2013 under President José “Pepe” Mujica, becoming the first country in the world to fully legalize recreational cannabis under a national state-controlled framework. The law created three legal channels for cannabis access: purchase at licensed pharmacies (for residents, up to 40 grams per month), home cultivation (up to six plants per person), and cannabis social clubs (registered groups of 15–45 members who cultivate collectively). Cannabis production and retail is regulated by the Institute for the Regulation and Control of Cannabis (IRCCA). The system is available to Uruguayan residents only — tourists cannot legally purchase cannabis at pharmacies, though they may use it if obtained from a resident. The Uruguayan model attracted global attention as a pragmatic state-controlled alternative to both prohibition and commercial liberalization. Medical use is available and has been part of the framework since inception.
Uruguay Cannabis Framework
Mexico’s cannabis legal situation is the product of judicial rather than legislative action. The Supreme Court (SCJN) issued a series of five rulings between 2015 and 2019 (the five-ruling threshold that creates binding jurisprudential criteria) declaring that the absolute prohibition of personal cannabis cultivation and consumption is unconstitutional, as it violates the rights to free development of personality and health. The practical effect is that personal use is constitutionally protected and law enforcement authorities are constrained from prosecuting personal users. The Mexican Senate passed a formal recreational cannabis bill in November 2020, but it was not approved by the Chamber of Deputies within the constitutional deadline and the process stalled. In June 2021, medical cannabis was formally regulated, permitting prescription cannabis products. Mexico remains in a legal limbo where use is effectively decriminalized by court order but no regulated retail market exists.
Colombia’s Constitutional Court issued Sentence C-221/94 in 1994, ruling that the criminal prohibition of personal drug use violates the constitutional right to free development of personality. Personal possession of up to 20 grams of cannabis is not subject to criminal penalties. Colombia subsequently enacted Law 1787 of 2016, creating a comprehensive regulatory framework for licensed medical and scientific cannabis cultivation and production. Colombia has since become one of the world’s largest medical cannabis export industries, leveraging its year-round outdoor growing climate, low production costs, and skilled agricultural workforce. Major pharmaceutical and cannabis companies have established significant operations in the country. Recreational cannabis beyond personal possession limits remains subject to criminal penalties, though enforcement of personal amounts is minimal.
Argentina’s Supreme Court (CSJN) ruled in the landmark 2009 Arriola case that the criminalization of personal drug use in private spaces is unconstitutional. This effectively decriminalized personal cannabis possession and use. In 2017, Argentina enacted Law 27.350, creating a comprehensive medical cannabis program. The 2020 decree 883/2020 significantly expanded the program, permitting registered patients to self-cultivate cannabis for personal medical use — an unusually progressive provision. The REPROCANN registry allows patients, caregivers, and CSCs (cannabis social clubs) to register and legally cultivate. A formal recreational legalization bill has been discussed but not advanced to a vote. Argentina has a vibrant cannabis advocacy community and one of Latin America’s most active civil society networks around cannabis policy.
Brazil’s ANVISA (National Health Surveillance Agency) issued Resolution RDC 327/2019, creating a formal regulatory framework for cannabis-derived health products. CBD-based products are available by prescription through authorized pharmacies and online pharmacies. THC-containing products require special ANVISA authorization. In June 2024, the Brazilian Supreme Court (STF) voted 6-5 to recognize that the criminalization of personal drug possession is unconstitutional — a landmark ruling that will require congressional response. However, a constitutional amendment (PEC 45) introduced by conservative legislators seeking to explicitly criminalize drug possession has complicated the picture. Brazil has the largest cannabis consumer population in Latin America, and its medical market is growing rapidly.
Chile’s Law 20.000 (2005) distinguishes between personal use and trafficking, decriminalizing possession of small amounts for personal consumption. A 2015 reform explicitly permitted personal cannabis cultivation of a limited number of plants at home. Medical cannabis prescriptions are available through licensed physicians since Law 21.020 (2017). Chile has one of the highest per-capita cannabis consumption rates in Latin America, and the country’s cannabis clubs have grown in number and visibility. A more comprehensive recreational legalization proposal has been discussed by Chilean legislators but has not advanced to a vote in the context of the country’s ongoing constitutional process.
Peru enacted Law 30681 in November 2017, legalizing the import, commercialization, and medical use of cannabis and its derivatives, including CBD and THC. The law was Peru’s first significant cannabis reform and positioned it as one of the early medical access nations in South America. Personal possession of small amounts has been decriminalized for personal use, with a legal threshold distinguishing personal consumption from trafficking. A broader recreational debate has begun in the Peruvian Congress but no formal recreational bill has advanced to a vote.
Bolivia is primarily known for its coca leaf culture, which is deeply embedded in indigenous tradition and formally protected under Bolivian law — a unique situation globally. Cannabis is technically illegal under the Ley del Régimen de la Coca y Sustancias Controladas, but enforcement has historically been minimal in rural and indigenous communities. No formal medical cannabis program exists. The country has not been a significant driver of cannabis reform in the region. That said, informal tolerance in some areas means that travelers may encounter cannabis use in practice, while formal legal risk remains.
Latin America’s leadership in cannabis reform is not accidental. Several structural factors have driven the region ahead of North America and Europe in establishing constitutional decriminalization frameworks:
Constitutional Rights Framework
Colombia (1994), Argentina (2009), and Mexico (2015–2019) all used constitutional rights arguments — right to privacy, free development of personality, autonomy — to decriminalize cannabis through court rulings rather than waiting for legislative consensus. This judicial path has proven faster and more durable than legislative reform.
Harm Reduction Movement
The devastating consequences of the War on Drugs — mass incarceration, cartel violence, corruption — have been most acutely felt in Latin America. This creates powerful political incentives for harm-reduction approaches that are less pressing in countries where drug violence is more distant.
Economic Opportunity
Countries like Colombia, Uruguay, and Peru have positioned licensed cannabis cultivation as an export opportunity, leveraging climate advantages and lower production costs to compete in the global medical cannabis market. Economic incentives have accelerated regulatory development.
Cannabis laws across Latin America vary significantly between countries and between what is technically legal versus what is practically enforced. Even in countries with constitutional decriminalization, foreign nationals may face different treatment than citizens. Always verify current local regulations before traveling.
Cannabis laws in Latin America are evolving rapidly, often driven by court rulings that may precede formal legislative action. This guide reflects the legal landscape as of 2026. Always verify current regulations with official local sources before traveling or making decisions. This page does not constitute legal advice.
